The TOM1 Antibody (CAB9273) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, generated in rabbits, exhibits high reactivity with human samples and has been validated for use in applications such as Western blotting.TOM1, also known as target of Myb1, plays a critical role in regulating protein trafficking and sorting within cells. By binding specifically to the TOM1 protein, this antibody enables accurate detection and analysis in a variety of cell types.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Mouse, Rat samples.
Product Name:
TOM1 Antibody
SKU:
CAB9273
Size:
20μL, 100μL
Reactivity:
Mouse, Rat
Conjugate:
Unconjugated
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
IMD85, TOM1
Positive Sample:
Mouse kidney, Mouse liver, Rat kidney, Rat liver
Cellular Localization:
Cytoplasm, Membrane, Peripheral Membrane Protein.
Calculated MW:
54kDa
Observed MW:
54kDa
This gene was identified as a target of the v-myb oncogene. The encoded protein shares its N-terminal domain in common with proteins associated with vesicular trafficking at the endosome. It is recruited to the endosomes by its interaction with endofin. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Purification Method
Affinity purification
Gene ID
10043
RRID
AB_2772678
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3.
Western blot analysis of various lysates using TOM1 Rabbit pAb (CAB9273) at 1:3000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 90s.
